Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31
      QxMD      Google Scholar   
Citation:
J. Clin. Oncol vol 37 (35) 3425-3435
Year:
2019
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Meta-Analysis
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
To be presented at the spotlight session at the San Antonio Breast Cancer Symposium Meeting 2018, December 4-8, 2018, San Antonio, Texas.
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
9
Parents:
2970  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
Genentech  
Grants:
U10CA180821, U24CA196171; U10CA180868 (NRG), UG1CA189867 (NRG NCORP), U10CA180822, U24CA196067 (NRG Biospecimen)  
Corr. Author:
 
Authors:
                         
Networks:
LAPS-MN026, NY021, PR028   
Study
Multiple Studies, or Legacy Studies in Alliance Study:
NCCTG-N9831, NSABP B-31
Phases:
3
Keywords:
ORIGINAL REPORTS, Breast Cancer